<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors studied the response to and side effects of long-term <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> (GC) therapy of systemic <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (SJRA) </plain></SENT>
<SENT sid="1" pm="."><plain>GC were given to 24 girls and 9 boys at the age of 4 to 15 years with classic SJRA in a mean dose 1.6 +/- 0.13 mg/kg (24.0 +/- 0.55 mg/day) for 6.3 +/- 0.55 years, on the average </plain></SENT>
<SENT sid="2" pm="."><plain>Mean duration of the disease was 7.1 +/- 0.55 years </plain></SENT>
<SENT sid="3" pm="."><plain>94% of the patients had lymphaticohypolastic constitution </plain></SENT>
<SENT sid="4" pm="."><plain>Long-term GC monotherapy in a dose 0.2-0.5 mg/kg/day failed to control a SJRA course and to produce an immunosuppressive effect while side effects were severe: inhibition of activity of the hypothalamohypophysioadrenal system and resultant hormone dependence (100%), <z:e sem="disease" ids="C0010481" disease_type="Disease or Syndrome" abbrv="">Cushing's syndrome</z:e> (97%), nanism (85%), <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> (64%), <z:e sem="disease" ids="C0442886" disease_type="Disease or Syndrome" abbrv="">secondary infections</z:e> (58%), <z:hpo ids='HP_0010885'>aseptic necrosis</z:hpo> of heads of the femur (52%) </plain></SENT>
<SENT sid="5" pm="."><plain>Oral GC treatment is not effective as first-line therapy of SJRA </plain></SENT>
<SENT sid="6" pm="."><plain>It should be used as adjuvant to immunodepressants </plain></SENT>
<SENT sid="7" pm="."><plain>Intraarticular and/or intravenous administration is preferable </plain></SENT>
</text></document>